Anzeige
Mehr »
Freitag, 10.10.2025 - Börsentäglich über 12.000 News
3 kritische Rohstoffe. 1 riesiges Becken. $2,26 Mrd. US-Finanzierung: Diese Aktie könnte die Nächste sein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40VVS | ISIN: US64136E1029 | Ticker-Symbol:
NASDAQ
09.10.25 | 21:59
19,110 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
NEUPHORIA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
NEUPHORIA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur NEUPHORIA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.09.Neuphoria Therapeutics Inc. Full Year Loss Drops2
29.09.Neuphoria schließt Phase-3-Studie zu sozialer Angststörung ab: Top-Line-Daten Anfang Q4 2025 erwartet5
29.09.Neuphoria completes patient visits in phase 3 social anxiety trial1
29.09.Neuphoria Therapeutics, Inc.: Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates223Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fiscal...
► Artikel lesen
29.09.Neuphoria Therapeutics Inc. - 10-K, Annual Report4
NEUPHORIA THERAPEUTICS Aktie jetzt für 0€ handeln
16.09.Neuphoria Therapeutics Inc. - 8-K, Current Report7
05.09.Pressmaster DMCC: One of the World's Largest Remote EEG Studies Begins: Neuphoria Partners with Monroe Institute488Brisbane, Australia--(Newsfile Corp. - September 5, 2025) - Neuphoria and the Monroe Institute announced the launch of an IRB-approved remote brainwave analysis research project involving 333 participants....
► Artikel lesen
04.09.Neuphoria Therapeutics, Inc.: Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)232BURLINGTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) ("Neuphoria" or the "Company"), a clinical-stage biotechnology company developing impactful treatments...
► Artikel lesen
18.07.Neuphoria Therapeutics Inc. - 8-K, Current Report15
27.05.Neuphoria Therapeutics, Inc.: Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting10
20.05.Neuphoria Therapeutics, Inc.: Neuphoria Provides First Quarter 2025 Business Updates498Cash runway into Q3 2026AFFIRM-1 Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025a7 nicotinic acetylcholine receptor PAM MK-1167 partnered with...
► Artikel lesen
20.05.Neuphoria Therapeutics Inc. - 8-K, Current Report3
20.05.Neuphoria Therapeutics Inc. - 10-Q, Quarterly Report5
12.02.Neuphoria To Receive $15 Mln Milestone Payment From Merck; Stock Up In Pre-market829KENILWORTH (NJ) (dpa-AFX) - Neuphoria Therapeutics Inc. (NEUP), a late-stage biotechnology company, Wednesday announced that a $15 million milestone payment is due from Merck & Co., Inc. (MRK).Shares...
► Artikel lesen
12.02.Neuphoria Therapeutics, Inc.: Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck675BURLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (Neuphoria or Company), a late-stage biotechnology developing impactful treatments for neuropsychiatric...
► Artikel lesen
26.12.24Pre-market Movers: Millennium Group International, Zoomcar, Color Star Technology, reAlpha Tech, Neuphoria Therapeutics1.827OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green Millennium Group International Holdings Limited (MGIH)...
► Artikel lesen
24.12.24XFRA CAPITAL ADJUSTMENT INFORMATION - 24.12.20241.199Das Instrument US09063M2052 BIONOMICS ADR/1/180 EQUITY wird cum Kapitalmassnahme gehandelt am 24.12.2024 und ex Kapitalmassnahme am 27.12.2024 The instrument US09063M2052 BIONOMICS ADR/1/180 EQUITY...
► Artikel lesen
23.12.24Neuphoria Therapeutics, Inc.: Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq780BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) ("Neuphoria" or the "Company") is pleased to announce that its previously announced scheme of arrangement...
► Artikel lesen
23.12.24XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.12.20241.285The following instruments on Boerse Frankfurt do have their last trading day on 23.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.12.2024ISIN NameAU000000ANL3 AMANI...
► Artikel lesen
16.12.24Bionomics Ltd: Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation596ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company) is pleased to announce that the Supreme Court of New South Wales...
► Artikel lesen
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1